Document is current
Any future updates will be listed below
-
Authors
Dragioti, Elena https://orcid.org/0000-0001-9019-4125
Radua, Joaquim
Solmi, Marco https://orcid.org/0000-0003-4877-7233
Arango, Celso https://orcid.org/0000-0003-3382-4754
Oliver, Dominic https://orcid.org/0000-0002-8920-3407
Cortese, Samuele
Jones, Peter B. https://orcid.org/0000-0002-0387-880X
Il Shin, Jae https://orcid.org/0000-0003-2326-1820
Correll, Christoph U.
Fusar-Poli, Paolo https://orcid.org/0000-0003-3582-6788
- License Information
-
More Information
Article History
Received: 29 December 2021
Revised: 9 April 2022
Accepted: 13 April 2022
First Online: 28 April 2022
Competing interests
: Dr. Arango has been a consultant to or has received honoraria or grants from Acadia, Angelini, Boehringer, Gedeon Richter, Janssen Cilag, Lundbeck, Minerva, Otsuka, Pfizer, Roche, Sage, Servier, Shire, Schering Plough, Sumitomo Dainippon Pharma, Sunovion and Takeda outside the current work. Paolo Fusar-Poli has received research or personal fees from Lundbeck, Angelini, Menarini and Boehringer Ingelheim outside the current work. Dr. Correll has been a consultant and/or advisor to or has received honoraria from AbbVie, Acadia, Alkermes, Allergan, Angelini, Aristo, Axsome, Damitsa, Gedeon Richter, Hikma, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Medscape, Merck, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Servier, SK Life Science, Sumitomo Dainippon, Sunovion, Supernus, Takeda, Teva, and Viatris. He provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Lundbeck, Rovi, Supernus, and Teva. He has received grant support from Janssen and Takeda. He received royalties from UpToDate and is also a stock option holder of LB Pharma. Dr. Jones is funded by the NIHR ARC East of England. The remaining authors declare no competing interests.
